research use only
Cat.No.S4184
| Related Targets | Integrase Bacterial Antibiotics Anti-infection Fungal COVID-19 Parasite Reverse Transcriptase HIV HCV Protease |
|---|---|
| Other Antiviral Inhibitors | Moroxydine HCl Aloperine GS-441524 Harringtonine Oleanolic Acid NGI-1 U18666A Aloin B LL-37 acetate Lapachol |
|
In vitro |
DMSO
: 34 mg/mL
(134.24 mM)
Water : 1 mg/mL Ethanol : Insoluble |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 253.26 | Formula | C10H15N5O3 |
Storage (From the date of receipt) | |
|---|---|---|---|---|---|
| CAS No. | 39809-25-1 | Download SDF | Storage of Stock Solutions |
|
|
| Synonyms | BRL-39123, VSA 671,NSC-759624 | Smiles | C1=NC2=C(N1CCC(CO)CO)N=C(NC2=O)N | ||
| In vitro |
Penciclovir is a guanine analogue antiviral drug used for the treatment of various herpesvirus infections. It is a nucleoside analogue which exhibits low toxicity and good selectivity. This compound is a selective antiherpesvirus agent, particularly against herpes simplex virus types 1 and 2 (HSV-1 and HSV-2) and varicella-zoster virus (VZV). It is converted to its active form, penciclovir triphosphate, by cellular kinases. It inhibits viral DNA polymerase by competing with deoxyguanosine triphosphate. It inhibits DNA synthesis of virus-infected cells. This chemical has in vitro activity against herpes simplex virus types 1 (HSV-1) and 2 (HSV-2). It does not inhibit DNA synthesis in non-infected cells. Mode of resistance is via qualitative changes in viral thymidine kinase or DNA polymerase. It has activity against several herpes viruses with IC50 of 37.9 μM for HHV-6A and 77.8 μM for HHV-6B. Herpes simplex virus-1 studies indicate that this compound induces apoptosis without causing much genotoxicity. |
References |
|
|---|
(data from https://clinicaltrials.gov, updated on 2024-05-22)
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT00878072 | Completed | Herpes Labialis |
Novartis Pharmaceuticals|Novartis |
March 25 2009 | Phase 2|Phase 3 |
| NCT00098059 | Completed | Herpes Simplex |
Novartis Pharmaceuticals|Novartis |
February 2005 | Phase 3 |
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.